How much does point Biopharma global (PNT) cost?

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Who is point Biopharma?

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer.

Why did point Biopharma global (PNT) rise 80% in early trading?

Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighting ...

Will Eli Lilly buy point Biopharma global?

Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday. Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based cancer...